Search Results - "Topp MS"

Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.

Authors: Waldschmidt J Fandrei D Hecker JS et al.

Source: Leukemia [Leukemia] 2026 May; Vol. 40 (5), pp. 1054-1057. Date of Electronic Publication: 2026 Mar 24.

Publication Type: Letter

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE; In Process

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.

Authors: Scheller L Zhou X Loeffler-Wirth H et al.

Source: HemaSphere [Hemasphere] 2025 Dec 08; Vol. 9 (12), pp. e70267. Date of Electronic Publication: 2025 Dec 08 (Print Publication: 2025).

Publication Type: Journal Article

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Authors: Topp MS Shah BD Jabbour E et al.

Source: Leukemia [Leukemia] 2026 Jul 17. Date of Electronic Publication: 2026 Jul 17.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial.

Authors: Lu, Jing Qiu, Huiying Wang, Ying et al.

Source: Journal of Hematology & Oncology. 9/2/2024, Vol. 17 Issue 1, p1-5. 5p.

Blinatumomab added to conditioning regimen of allogeneic hematopoietic stem cell transplantation for adult MRD-positive acute lymphoblastic leukemia: a single-center case series.

Authors: Fu, Hui Zhao, Yanmin Fu, Huarui et al.

Source: Hematology. Dec2025, Vol. 30 Issue 1, p1-6. 6p.

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Authors: Claiborne, John Preston Tsai, Hua-Ling Ghiaur, Gabriel et al.

Source: Leukemia & Lymphoma. Apr2026, Vol. 67 Issue 5, p1066-1079. 14p.

BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma.

Authors: Jin, Chengwei Deng, Jing Jiang, Ying et al.

Source: Hematology. Dec2025, Vol. 30 Issue 1, p1-8. 8p.

Enhancement of CAR-T cell efficacy and persistence via CD30 costimulation and NF-κB signaling.

Authors: Su, Yang Yang, Guang Chen, Bi et al.

Source: Molecular Cancer. 11/13/2025, Vol. 24 Issue 1, p1-17. 17p.

BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study.

Authors: Rodriguez, Cesar Rodriguez, Tulio Kentos, Alain et al.

Source: Leukemia & Lymphoma. Nov2025, Vol. 66 Issue 11, p2108-2117. 10p.

Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China.

Authors: Zha, Jie Fan, Liyuan Yi, Shuhua et al.

Source: Journal of Hematology & Oncology. 8/23/2021, Vol. 14 Issue 1, p1-4. 4p.

Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review.

Authors: Kim, Dong Hyun Cha, Seungah Koh, Youngil et al.

Source: Leukemia & Lymphoma. May2026, Vol. 67 Issue 6, p1317-1326. 10p.

Diffuse large B-cell lymphoma outcomes in an urban safety-net cohort: functional status, clinical risk, and treatment feasibility.

Authors: Thida, Aye Nasirikhaneghah, Erfan Chiu, Edwin

Source: Leukemia & Lymphoma. May2026, Vol. 67 Issue 6, p1299-1307. 9p.

Blinatumomab use in patients with CD19 positive B-ALL and hepatic dysfunction.

Authors: Fu, Cynthia Ngo, Dat Tinajero, Jose et al.

Source: Leukemia & Lymphoma. Feb2025, Vol. 66 Issue 2, p320-324. 5p.

Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy.

Authors: Huang, Si‐Man Wan, Chao‐Ling Cao, Han‐Yu et al.

Source: Clinical Case Reports. Dec2023, Vol. 11 Issue 12, p1-5. 5p.

Real-world results of first-line ABVD in patients with classic Hodgkin's lymphoma at a neoplastic disease institute in Lima, Peru.

Alternate Title: Resultados del mundo real del ABVD de primera línea en pacientes con linfoma de Hodgkin clásico en un instituto de enfermedades neoplásicas en Lima, Perú.

Authors: Salinas Agramonte, Luis Valencia Laurel, Grethel Alcarraz, Cindy et al.

Source: Revista Medica Herediana. Oct-Dec2025, Vol. 36 Issue 4, p332-344. 13p.

Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies.

Authors: Sierro-Martínez, Belén Guijarro-Albaladejo, Beatriz Fernández-Cisnal, Ricardo et al.

Source: Journal of Translational Medicine. 8/19/2025, Vol. 23 Issue 1, p1-14. 14p.

Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage.

Authors: Azevedo RS Jabbour E Jain N et al.

Source: Leukemia [Leukemia] 2026 Jul 16. Date of Electronic Publication: 2026 Jul 16.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance.

Authors: Xue C Wu C Zhang Y et al.

Source: Annals of hematology [Ann Hematol] 2026 May 06; Vol. 105 (7). Date of Electronic Publication: 2026 May 06.

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia.

Authors: Ngo, Dat Tinajero, Jose Song, Joo Y. et al.

Source: Leukemia & Lymphoma. Dec2024, Vol. 65 Issue 13, p2016-2024. 9p.

CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.

Transliterated Title: CXCR4-gerichtete Theranostics in der Hämato-Onkologie: Möglichkeiten und Herausforderungen.

Authors: Werner R Haug A Buske C et al.

Source: Nuklearmedizin. Nuclear medicine [Nuklearmedizin] 2024 Apr; Vol. 63 (2), pp. 57-61. Date of Electronic Publication: 2024 Jan 08.

Publication Type: Journal Article

Journal Info: Publisher: Thieme Country of Publication: Germany NLM ID: 7609387 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2567-6407 (Electronic) Linking ISSN: 00295566 NLM ISO Abbreviation: Nuklearmedizin Subsets: MEDLINE